{"nctId":"NCT02467842","briefTitle":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects","startDateStruct":{"date":"2014-10"},"conditions":["Influenza"],"count":1503,"armGroups":[{"label":"NBP607-QIV","type":"EXPERIMENTAL","interventionNames":["Biological: NBP607-QIV"]},{"label":"NBP607-Y","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: NBP607-Y"]},{"label":"NBP607-V","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: NBP607-V"]}],"interventions":[{"name":"NBP607-QIV","otherNames":[]},{"name":"NBP607-Y","otherNames":[]},{"name":"NBP607-V","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults aged 19 years and older\n* Those who are able to comply with the requirements for the study\n* If women, a negative pregnancy test and willingness to use birth control measures for the entire study duration\n\nExclusion Criteria:\n\n* Disorders in immune function\n* Any malignancy or lymphoproliferative disorder\n* History of Guillain-Barré syndrome\n* Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time\n* Experience of fever (\\>38.0 ℃) within 24 hours following vaccination\n* Body temperature \\>38.0 ℃ at the vaccination day\n* Concomitant medications/therapy such as immunosuppressants or immune modifying drugs, systemic corticosteroids, immunoglobulins, blood or blood- derived products within 3 months\n* Influenza vaccination within 6 months\n* Subjects who have participated in other interventional study within 4 weeks\n* Any vaccination within 1 month\n* Those who are planning to receive any vaccine within 1 month from the study vaccine\n* Individuals with any serious chronic or progressive disease\n* Pregnant or breast-feeding women\n* Any other reason that in the opinion of the investigator might interfere with the study","healthyVolunteers":true,"sex":"ALL","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean HI Titers (GMTs) After Vaccination in All Subjects","description":"GMTs of anti-influenza antibodies were measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. For each A strain, the titers were made with the pooled TIV group (NBP60-Y and NBP607-V).\n\nFor each A strain, the comparion was made with the pooled TIV groups (Y+V/QIV). For each B strain, the comparison was made with the corresponding TIV group(i.e. for B/Yamagata, Geometric Mean Titer Ratio (GMR) is Y/QIV).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"329.76","spread":null},{"groupId":"OG001","value":"334.98","spread":null},{"groupId":"OG002","value":"334.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"401.21","spread":null},{"groupId":"OG001","value":"377.34","spread":null},{"groupId":"OG002","value":"377.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163.74","spread":null},{"groupId":"OG001","value":"144.65","spread":null},{"groupId":"OG002","value":"123.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124.82","spread":null},{"groupId":"OG001","value":"93.29","spread":null},{"groupId":"OG002","value":"112.20","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroconversion Rate (SCR) After Vaccination in All Subjects","description":"SCR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of \\<1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10\n\nFor each A strain, the comparion was made with the pooled TIV groups (Y+V minus QIV). For each B strain, the comparison was made with the corresponding TIV group(i.e. for B/Yamagata, Difference of SCR (Diff.SCR) is Y minus QIV).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.41","spread":null},{"groupId":"OG001","value":"52.56","spread":null},{"groupId":"OG002","value":"50.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.20","spread":null},{"groupId":"OG001","value":"46.09","spread":null},{"groupId":"OG002","value":"46.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.72","spread":null},{"groupId":"OG001","value":"36.66","spread":null},{"groupId":"OG002","value":"24.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.75","spread":null},{"groupId":"OG001","value":"43.13","spread":null},{"groupId":"OG002","value":"52.66","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroprotection Rate (SPR) of NBP607-QIV in the Elderly Subject Aged ≥60 Years","description":"SPR of NBP607-QIV was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroprotection was defined as the proportion of subjects whose post-vaccination HI titer increased to ≥1:40.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.05","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroconversion Rate (SCR) of NBP607-QIV in the Elderly Subject Aged ≥60 Years","description":"SCR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of \\<1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.87","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Ratio (GMR) of NBP607-QIV in the Elderly Subject Aged ≥60 Years","description":"GMR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. GMR was defined as the fold-rise of the geometric mean HI titer from pre- to post-vaccination.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.61","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean HI Titers (GMTs) of Each B Strain After Vaccination in All Subjects","description":"GMTs of anti-influenza antibodies were measured for B strains: B/Victoria, and B/Yamagata.\n\nFor each B strain, the comparison was made with the TIV group which did not contain the correponding B strain (i.e. for B/Yamagata, Geometric Mean Titer Ratio (GMR) is V/QIV).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163.74","spread":null},{"groupId":"OG001","value":"144.65","spread":null},{"groupId":"OG002","value":"123.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124.82","spread":null},{"groupId":"OG001","value":"93.29","spread":null},{"groupId":"OG002","value":"112.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Rate (SCR) of B Strain After Vaccination in All Subjects","description":"SCR was measured for each B strain: B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of \\<1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.72","spread":null},{"groupId":"OG001","value":"36.66","spread":null},{"groupId":"OG002","value":"24.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.75","spread":null},{"groupId":"OG001","value":"43.13","spread":null},{"groupId":"OG002","value":"52.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroprotection Rate (SPR) of NBP607-QIV in the Adults Aged 19 to 59 Years","description":"SPR of NBP607-QIV was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroprotection was defined as the proportion of subjects whose post-vaccination HI titer increased to ≥1:40.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.16","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Rate (SCR) of NBP607-QIV in the Adults Aged 19 to 59 Years","description":"SCR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of \\<1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.70","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Ratio (GMR) of NBP607-QIV in the Subjects Aged 19 to 59 Years","description":"GMR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. GMR was defined as the fold-rise of the geometric mean HI titer from pre- to post-vaccination","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.08","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":752},"commonTop":["Tenderness","Pain","Myalgia","Fatigue/Malaise","Headache"]}}}